Approximately 24 patients with active non-infectious uveitis, in at least one eye, requiring intensification of systemic immunosuppressive therapy will be enrolled and randomized to receive intravitreal LFG316 or conventional therapy (investigator's discretion). Only one eye (the study eye) will be treated with LFG316 and the other eye (fellow eye) will be treated at the investigator's discretion.Throughout the study, the fellow eye may be treated as needed; except that certain systemic medications are prohibited There will be 1 screening and 8 scheduled visits over 85 days for a total of 9 site visits for all patients.